Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.33 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | RXRB | P28702 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2084576 | 0.74 | RAPGEF4 (0.32) | RAPGEF4 | |
| SCHEMBL31018114 | 0.74 | RAPGEF4 (0.32) | RAPGEF4 | |
| SCHEMBL10272138 | 0.72 | TP53 (0.33) | RAPGEF4 | |
| SCHEMBL18544731 | 0.65 | CES2 (0.35) | RAPGEF4CES2 | |
| SCHEMBL9861932 | 0.64 | CA1 (0.52) | AGBL2RAPGEF4RXRARXRBCES2 | |
| SCHEMBL20088538 | 0.64 | TSHR (0.33) | RAPGEF4 | |
| SCHEMBL13170375 | 0.63 | RAPGEF4 (0.50) | RAPGEF4RXRARXRBCES2 | |
| SCHEMBL17189818 | 0.63 | ACHE (0.36) | CES2 | |
| SCHEMBL2085234 | 0.63 | RAPGEF4 (0.33) | RAPGEF4 | |
| SCHEMBL16139576 | 0.61 | PDE2A (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11174256-B2 | Imidazopyridine derivatives | GILEAD SCIENCES, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-20200165248-A1 | IMIDAZOPYRIDINE DERIVATIVES | GILEAD SCIENCES, INC. | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11174256-B2 | Imidazopyridine derivatives | TPMT, IRAK4, CFTR | AGBL2 2245/4885RAPGEF4 1244/4885RXRA 1965/4885 |
| US-20200165248-A1 | IMIDAZOPYRIDINE DERIVATIVES | TPMT, IRAK4, CFTR | AGBL2 2245/4885RAPGEF4 1244/4885RXRA 1965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.